ClinicalTrials.gg
Status unknownNCT01530828Updated Aug 9, 2013

IRT in Infants With Intestinal Perforation

An observational study in Intestinal Perforation and Necrotizing Enterocolitis, sponsored by Children's Hospitals and Clinics of Minnesota. Status unknown at 1 site in United States. Open to participants aged 1 Day to 16 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-09.

Sponsored by Children's Hospitals and Clinics of Minnesota · Observational

The sponsor has not verified this record recently (last verified Aug 2013), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Ages
1 Day to 16 Days
Sex
All
01

Study summary

This study is designed to evaluate a novel tool to aid in the diagnosis of intestinal perforation in infants who are at high risk. Analysis of perforation rates of all infants in the three largest participating sites shows that the majority of infants with perforation will do so prior to day of life 21. This study will target the group of infants at highest risk for IP, those with birth weight less than 1000 grams, within the time frame most likely to capture the perforation. Hypothesis: An IRT value exists that can adequately differentiate premature infants with and without intestinal perforation in the first 3 weeks of life.

Read the detailed description

At least 300 infants age 1-16 days will be enrolled. IRT values will be obtained daily through day of life 21, if the infant is already having labs drawn that day. The primary outcomes will be intestinal perforation and/or death on or before day of life 21. Each patient will be followed until death or discharge. Discharge will be defined as the release of the infant to home. Infants who are transferred to another NICU may be followed if the receiving NICU is one of the investigational sites. Transfer includes the release of the infant to outside units or other units within the same hospital. The purpose of this follow up is to obtain serial IRT values through day of life 21.

02

Conditions studied

  • Intestinal Perforation
  • Necrotizing Enterocolitis

Keywords

  • Immunoreactive Trypsinogen
  • Nectrotizing Enterocolitis
  • Premature Infants
  • Serial IRT
03

In context

Intestinal Perforation

36 studies on the registry are indexed under Intestinal Perforation; 5 are open to participants now.

This study's planned enrollment of 300 is above the median of 203 across 20 observational studies indexed under Intestinal Perforation.

Browse Intestinal Perforation studies →

Lead sponsor

Children's Hospitals and Clinics of Minnesota is the lead sponsor of 49 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 16 Days
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Premature infants less than 1000 grams, age 1-16 days

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Birth weight less than 1000 grams
  • Admitted to investigative site within first 16 days of life.

Exclusion criteria

Exclusion Criteria:

  • Evidence of Intestinal perforation in utero
  • Suspected or confirmed custic fibrosis
  • Abdominal wall defect or intestinal atresia
  • Concomitant medical condition that may create an unacceptable risk.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)

Groups and cohorts

  • Premature infants

    Weight less than 1000 grams, age 1 - 16 days.

06

What researchers measure

Primary outcomes

  1. To determine the onset and duration of elevation in serum IRT in infants with intestinal perforation.

    Time frame: 3 years

Secondary outcomes

  1. Determine if factors other than intestinal perforation affect serum IRT.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Children's Hospitals & Clinics of Minnesota
    St. Paul, Minnesota 55102, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01530828
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Responsible party
Nicole Birge (Prinicpal Investigator, Children's Hospitals and Clinics of Minnesota) — Principal investigator
First posted
Feb 10, 2012
Start date
Aug 2010
Primary completion
Sep 2013 (estimated)
Completion
Aug 2014 (estimated)
Last update
Aug 9, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion